Business Context and Reporting Period
Company: Gyrodyne, LLC (GYRO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Accounting Basis: Liquidation Basis of Accounting (imminent dissolution)
Business Overview: Gyrodyne manages a portfolio of medical office and industrial properties in Suffolk (Flowerfield) and Westchester (Cortlandt Manor) Counties, New York. The company's strategy is to pursue land entitlements to increase development flexibility, sell the properties at enhanced values, settle debts, and distribute remaining proceeds to shareholders before dissolving.
Key Financial Metrics
| Metric | December 31, 2024 | December 31, 2023 |
|---|---|---|
| Net Assets (Liquidation Basis) | $30,596,313 | $30,721,034 |
| Estimated Distribution Per Share | $13.91 | $19.51 |
| Real Estate Held for Sale (Net Realizable Value) | $50,388,000 | $53,780,000 |
| Cash and Cash Equivalents | $5,899,232 | $3,492,692 |
| Total Liabilities | $26,063,778 | $26,683,730 |
| Mortgage Loans Payable | $11,169,922 | $10,981,068 |
| Estimated Liquidation & Operating Costs (Net of Receipts) | $11,089,746 | $11,108,640 |
| Shares Outstanding | 2,199,308 | 1,574,308 |
Operating Performance (2024):
- Rent and Reimbursements: $3,105,989
- Operating Costs: $1,898,920
- Net Operating Income: $1,207,069
- Land Entitlement Costs Incurred: $422,328
Material Changes vs. Prior Period
- Net Assets Decrease: Net assets declined by $124,721 (0.4%) from 2023 to 2024. This decrease is primarily driven by a $3,392,000 reduction in the estimated net realizable value of real estate and increased costs associated with a one-year extension of the liquidation timeline ($1,912,000).
- Capital Raise: The decline was partially offset by net proceeds of $4,418,380 from a rights offering completed in March 2024, which issued 625,000 new shares.
- Dilution: The issuance of new shares at $8.00 per share (below the pro-forma net asset value of ~$16.12) contributed to a decrease in estimated distribution per share from $19.51 to $13.91.
- Real Estate Valuation: The net realizable value of the Cortlandt Manor property decreased by $3,480,000, while the Flowerfield property increased by $88,000, reflecting market conditions and entitlement status.
Guidance, Outlook, and Risks
Liquidation Timeline: Management anticipates completing the process of negotiating purchase agreements, securing final approvals, and consummating sales by December 31, 2026. However, the company notes there can be no assurance this deadline will be met.
Outlook:
- Flowerfield: Subdivision approval is expected in mid-2025, contingent on the resolution of the Article 78 Proceeding.
- Cortlandt Manor: Subdivision approval could be received in mid-2026.
- Future Costs: The company estimates incurring an additional $1.24 million in land entitlement costs through the end of the liquidation period.
Material Risks and Contingencies:
- Article 78 Proceeding: A legal challenge by the Village of Head of the Harbor and others seeks to annul the preliminary subdivision approval for Flowerfield. While the Supreme Court dismissed the petition in October 2024, petitioners have appealed. The outcome and timeline of this appeal are critical to the sale of Flowerfield.
- Settlement Price Floor: A 2015 class action settlement prohibits selling properties below their 2014 appraised values. While current values exceed this floor, a market downturn could restrict sale options.
- Activist Shareholders: The company incurred approximately $950,000 in cumulative costs related to a 2023 activist campaign by Star Equity Fund, LP, which was resolved via a cooperation agreement.
- Debt Maturity: Significant mortgage debt matures in 2028, though the company intends to modify loan terms or refinance prior to the 2026 liquidation target.
Investor Verification Checklist
- Article 78 Appeal Status: Verify the current status of the appeal regarding the Flowerfield subdivision approval, as this is the primary blocker to selling the largest asset.
- Real Estate Valuation Assumptions: Review the independent appraisals and discounted cash flow models used to determine the $50.4 million net realizable value, noting the significant $3.4 million write-down in Cortlandt Manor.
- Liquidation Cost Estimates: Assess the reasonableness of the $11.1 million estimated liability for liquidation and operating costs, including legal fees and entitlement expenses.
- Debt Covenants: Confirm compliance with loan covenants and the feasibility of modifying debt terms to align with the 2026 liquidation timeline.
- Shareholder Distribution Calculation: Understand that the $13.91 per share estimate is based on liquidation assumptions and may be reduced by unforeseen costs or delays.